Medical treatment of mesothelioma: Anything new?

Nagio Takigawa, Katsuyuki Kiura, Takumi Kishimoto

Research output: Contribution to journalReview articlepeer-review

7 Citations (Scopus)


In the present report, we review the current standard and investigational treatments of malignant pleural mesothelioma (MPM). Several studies have reported the use of gemcitabine and cisplatin as an induction chemotherapy in combination with extrapleural pneumonectomy (EPP) and thoracic radiation in a combined-modality approach for resectable MPM. Since the combination of cisplatin with pemetrexed was applied as the standard first-line regimen for unresectable MPM, the combination as an induction chemotherapy regimen has been proven effective in phase 2 trials. In addition, intensity-modulated radiation therapy and proton therapy have been introduced as new radiation methods into the combined modality. Hyperthermic intraoperative chemotherapy following EPP appears effective with acceptable toxicity. In addition, clinical studies that include molecular targeting agents, immunotherapy, and gene therapy have all been conducted. Thus, although there are numerous hopeful treatments for MPM, the benefits of these regimens remain to be proven in a randomized clinical setting.

Original languageEnglish
Pages (from-to)265-271
Number of pages7
JournalCurrent Oncology Reports
Issue number4
Publication statusPublished - Aug 2011


  • Chemotherapy
  • Combined modality
  • Extrapleural pneumonectomy
  • Gene therapy
  • Immunotherapy
  • Malignant pleural mesothelioma
  • Molecular-targeted therapy
  • Pemetrexed
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Medical treatment of mesothelioma: Anything new?'. Together they form a unique fingerprint.

Cite this